The liver fat content and its relationships with insulin resistance in schizophrenia patients receiving olan-zapine or aripiprazol:a randomized comparative study
10.3969/j.issn.1002-0152.2015.11.002
- VernacularTitle:奥氮平、阿立哌唑治疗精神分裂症后肝脏脂肪含量变化及其与胰岛素抵抗的关系
- Author:
Fangbin CHEN
;
Jian SUN
;
Tongjun YAN
;
Leping XU
;
Huanlin WANG
- Publication Type:Journal Article
- Keywords:
Schizophrenia;
Olanzapine;
Aripiprazole;
Lipid metabolism;
Insulin resistance
- From:
Chinese Journal of Nervous and Mental Diseases
2015;(11):646-650
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the liver fat content (LFC) in schizophrenia patients during olanzapine or aripipra?zol treatment, and to explore the relation between LFC and insulin resistance (IR). Methods Schizophrenia patients were randomly administered with olanzapine (10~25 mg/d, n=57) or aripiprazole (15~30 mg/d, n=47) for eight weeks. All sub?jects underwent sonographic quantification of LFC and homeostasis model assessment of insulin resistance index (HOMA-IR) once 0, 4, 8 weeks of treatment. Results Compared with baseline, the levels of HOMA-IR significantly in?creased after a 4-week and an 8-week of olanzapine treatment, and so did the LFC after an 8-week of olanzapine treat?ment (P<0.05). The levels of LFC (P>0.05) or HOMA-IR (P>0.05) did not significantly changed at week 4 and 8 in ar?ipiprazol group. The increment of LFC, HOMA-IR at week 8 was significantly higher in olanzapine group than that in ar?ipiprazol group (P<0.05). The change of LFC after 8-weeks olanzapine treatment was positively correlated with the change of HOMA-IR (r=0.298, P=0.036). Conclusion Olanzapine treatment increases whereas aripiprazol has little ef?fect on liver fat and insulin resistance in schizophrenia.
